Literature DB >> 20567026

Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.

XinXia Chang1, HongMei Yan, Jing Fei, MingHong Jiang, HongGuang Zhu, DaRu Lu, Xin Gao.   

Abstract

High-calorie food leads to nonalcoholic fatty liver disease (NAFLD) through dysregulation of genes involved in lipid metabolism, but the precise mechanism remains unclear. DNA methylation represents one of the mechanisms that contributes to dysregulation of gene expression via interaction with environmental factors. Berberine can alleviate fatty liver in db/db and ob/ob mice. Here, we investigated whether DNA methylation is involved in the pathogenesis of NAFLD induced by a high-fat diet (HFD) and whether berberine improves NAFLD through influencing the methylation status of promoters of key genes. HFD markedly decreased the mRNA levels encoding CPT-1alpha, MTTP, and LDLR in the liver. In parallel, DNA methylation levels in the MTTP promoter of rats with NAFLD were elevated in the liver. Interestingly, berberine reversed the downregulated expression of these genes and selectively inhibited HFD-induced increase in the methylation of MTTP. Consistently, berberine increased hepatic triglyceride (TG) export and ameliorated HFD-induced fatty liver. Furthermore, a close negative correlation was observed between the MTTP expression and its DNA methylation (at sites -113 and -20). These data indicate that DNA methylation of the MTTP promoter likely contributes to its downregulation during HFD-induced NAFLD and, further, that berberine can partially counteract the HFD-elicited dysregulation of MTTP by reversing the methylation state of its promoter, leading to reduced hepatic fat content.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567026      PMCID: PMC2918435          DOI: 10.1194/jlr.M001958

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  40 in total

1.  Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice.

Authors:  M Raabe; M M Véniant; M A Sullivan; C H Zlot; J Björkegren; L B Nielsen; J S Wong; R L Hamilton; S G Young
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

3.  Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation.

Authors:  H Kuriyama; S Yamashita; I Shimomura; T Funahashi; M Ishigami; K Aragane; K Miyaoka; T Nakamura; K Takemura; Z Man; K Toide; N Nakayama; Y Fukuda; M C Lin; J R Wetterau; Y Matsuzawa
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

4.  Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339.

Authors:  John S Millar; Debra A Cromley; Mary G McCoy; Daniel J Rader; Jeffrey T Billheimer
Journal:  J Lipid Res       Date:  2005-07-01       Impact factor: 5.922

Review 5.  Nonalcoholic fatty liver disease.

Authors:  Leon A Adams; Paul Angulo; Keith D Lindor
Journal:  CMAJ       Date:  2005-03-29       Impact factor: 8.262

6.  Regulation of hamster hepatic microsomal triglyceride transfer protein mRNA levels by dietary fats.

Authors:  A J Bennett; M A Billett; A M Salter; D A White
Journal:  Biochem Biophys Res Commun       Date:  1995-07-17       Impact factor: 3.575

7.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.

Authors:  Kitt Falk Petersen; Sylvie Dufour; Douglas Befroy; Michael Lehrke; Rosa E Hendler; Gerald I Shulman
Journal:  Diabetes       Date:  2005-03       Impact factor: 9.461

8.  Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.

Authors:  Weijia Kong; Jing Wei; Parveen Abidi; Meihong Lin; Satoru Inaba; Cong Li; Yanling Wang; Zizheng Wang; Shuyi Si; Huaining Pan; Shukui Wang; Jingdan Wu; Yue Wang; Zhuorong Li; Jingwen Liu; Jian-Dong Jiang
Journal:  Nat Med       Date:  2004-11-07       Impact factor: 53.440

9.  Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.

Authors:  Parveen Abidi; Yue Zhou; Jian-Dong Jiang; Jingwen Liu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-08-11       Impact factor: 8.311

10.  Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study.

Authors:  Anthony J G Hanley; Ken Williams; Andreas Festa; Lynne E Wagenknecht; Ralph B D'Agostino; Judy Kempf; Bernard Zinman; Steven M Haffner
Journal:  Diabetes       Date:  2004-10       Impact factor: 9.461

View more
  55 in total

Review 1.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

2.  Berberine protects steatotic donor undergoing liver transplantation via inhibiting endoplasmic reticulum stress-mediated reticulophagy.

Authors:  Nan Zhang; Mingwei Sheng; Man Wu; Xinyue Zhang; Yijie Ding; Yuanbang Lin; Wenli Yu; Shusen Wang; Hongyin Du
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-25

Review 3.  Biologically active isoquinoline alkaloids covering 2014-2018.

Authors:  Xiao-Fei Shang; Cheng-Jie Yang; Susan L Morris-Natschke; Jun-Cai Li; Xiao-Dan Yin; Ying-Qian Liu; Xiao Guo; Jing-Wen Peng; Masuo Goto; Ji-Yu Zhang; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2020-07-29       Impact factor: 12.944

4.  Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.

Authors:  Lingling Wang; Zhandong Jia; Bangcai Wang; Bin Zhang
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

5.  Gestational exercise protects adult male offspring from high-fat diet-induced hepatic steatosis.

Authors:  Ryan D Sheldon; A Nicole Blaize; Justin A Fletcher; Kevin J Pearson; Shawn S Donkin; Sean C Newcomer; R Scott Rector
Journal:  J Hepatol       Date:  2015-08-29       Impact factor: 25.083

6.  Berberine reverses abnormal expression of L-type pyruvate kinase by DNA demethylation and histone acetylation in the livers of the non-alcoholic fatty disease rat.

Authors:  Yuhao Zhang; Xinxia Chang; Xiao Song; Chen Chen; Hongyan Chen; Zhiqiang Lu; Xin Gao; Daru Lu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21.

Authors:  Yixuan Sun; Mingfeng Xia; Hongmei Yan; Yamei Han; Feifei Zhang; Zhimin Hu; Aoyuan Cui; Fengguang Ma; Zhengshuai Liu; Qi Gong; Xuqing Chen; Jing Gao; Hua Bian; Yi Tan; Yu Li; Xin Gao
Journal:  Br J Pharmacol       Date:  2017-12-15       Impact factor: 8.739

8.  Epigenetic Alterations in Human Liver From Subjects With Type 2 Diabetes in Parallel With Reduced Folate Levels.

Authors:  Emma Nilsson; Ashok Matte; Alexander Perfilyev; Vanessa D de Mello; Pirjo Käkelä; Jussi Pihlajamäki; Charlotte Ling
Journal:  J Clin Endocrinol Metab       Date:  2015-09-29       Impact factor: 5.958

9.  Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease.

Authors:  Weihan Zhao; Lijuan Liu; Yunliang Wang; Tangyou Mao; Junxiang Li
Journal:  Exp Ther Med       Date:  2015-11-09       Impact factor: 2.447

10.  Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.

Authors:  Runbin Sun; Na Yang; Bo Kong; Bei Cao; Dong Feng; Xiaoyi Yu; Chun Ge; Jingqiu Huang; Jianliang Shen; Pei Wang; Siqi Feng; Fei Fei; Jiahua Guo; Jun He; Nan Aa; Qiang Chen; Yang Pan; Justin D Schumacher; Chung S Yang; Grace L Guo; Jiye Aa; Guangji Wang
Journal:  Mol Pharmacol       Date:  2016-12-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.